Search results

Skip to results

Type

Status

Last updated

Showing 1 to 6 of 6 results for enoxaparin

  1. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing venous thromboembolism after total hip or total knee replacement in adults.

    Technology appraisal guidance
    Published
    22 April 2009
    View recommendations

    Sections for TA170

  2. Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245)

    Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after total hip or knee replacement in adults.

    Technology appraisal guidance
    Published
    25 January 2012
    View recommendations

    Sections for TA245

  3. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing a pulmonary embolism (PE) or another deep vein thrombosis in adults.

    Technology appraisal guidance
    Published
    25 July 2012
    View recommendations

    Sections for TA261

  4. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.

    Technology appraisal guidance
    Published
    26 June 2013
    View recommendations

    Sections for TA287

  5. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing venous thromboembolism after hip or knee replacement surgery in adults.

    Technology appraisal guidance
    Published
    24 September 2008
    View recommendations

    Sections for TA157

  6. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

    Technology appraisal guidance
    Published
    4 June 2015
    View recommendations

    Sections for TA341